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DIPEA ,The importance of uracil and its annelated derivatives is well
recognised by synthetic as well as by biological chemists.1 The
preparation of naturally occurring complex molecules containing
a uracil ring poses signiﬁcant synthetic challenges.2 In this regard,
the synthetic exploitation of the nucleophilic double bond of uracil
is an important strategy for the synthesis of a variety of potential
products.3 Pyrido[2,3-d]pyrimidines represent a broad class of
annelated uracils of natural occurrence, which has received consid-
erable attention over the past years due to its wide range of biolog-
ical activities. Compounds with this ring system have diverse
pharmacological activity such as antibacterial,4 antitumour,5 car-
diotonic,6 hepatoprotective,6a antihypertensive6a and antibronchi-
tics.7 Some of them exhibit antiallergic,8 antimalarial9 and
analgesic10 properties, and also act as inhibitors of adenosine ki-
nase.11 Hence, for the preparation of these molecules, there has
been growing interest in the synthetic manipulation of uracils.12
a-Cyclisation of tertiary amines is a mechanistically intriguing
and synthetically useful cyclisation process, which has not re-
ceived much attention. Certain tertiary anilines or enamines and
enamine esters undergo such cyclisation leading to annelated pyr-
rolidines. Suschitzky and Meth-Cohn have coined the term ‘tertiary
amine effect’ for such a process,13 which has been further devel-
oped by Reinhoudt and Verboom.14
In one of our earlier studies, we synthesised some novel pyrro-
lizino[2,3-d]pyrimidines from the reaction of 6-tertiaryamino
uracils with dimethylacetylenedicarboxylate (DMAD) via a-cycli-
sation of tertiary amines.15 In our continued interest in uracilsll rights reserved.
: +91 376 2370011.
an).and the synthesis of diverse heterocyclic compounds of biological
importance,16 we report here the synthesis of some novel classes
of spirosubstituted pyrido[2,3-d]pyrimidines by exploring the ter-
tiary amine effect reaction strategy (Scheme 1).3d
3
5g-h
Scheme 1.
244 B. Baruah, P. J. Bhuyan / Tetrahedron Letters 50 (2009) 243–2452-Chloro-3-formyl-N,N-dimethyl uracils 1 were prepared from
N,N-dimethyl-6-hydroxy uracil by following our own reported
method,17 which on treatment with piperidine 3a afforded the 5-
formyl-6-pipiridino uracil derivative 3a.18 The compound 3a on
treatment with N,N-dimethyl barbituric acid 4a in the presence
of diisopropylethylamine (DIPEA) under stirring conditions in eth-
anol at room temperature and then under reﬂuxing conditions
afforded after work up the spirosubstituted pyrido[2,3-d]pyrimi-
dine 5a in excellent yield.19 The structure of the compound was
ascertained from the spectroscopic data and elemental analysis.
The 1H NMR spectra showed the absence of the aldehyde proton
and splitting of the protons of the tertiary amino group. It showed
the presence of two additional N-Me groups at d 3.35 and 3.45 and
the presence of two isolated protons at d 3.79 as a singlet. More-
over, one triplet appeared at d 1.89 for a single proton. The mass
spectra showed the molecular ion peak at 390.3 (M+H)+.
The generality of the reaction was established by synthesising
various cyclic and acyclic tertiary amino uracil derivatives 2a–d
from 1, and utilising them with N,N-dimethylbarbituric acid/N-
methylbarbituric acid 4a–b under thermal conditions using etha-
nol as solvent and diisopropylethylamine as base, which afforded
the diverse annelated spirosubstituted pyrido[2,3-d]pyrimidines
5b–h in good to excellent yield. The structure of the compounds
was determined from the spectroscopic data and elemental analy-
sis. Our observations are recorded in Table 1. In our study, it is ob-
served that the reactivity of 6-pyrrolidino uracils are
comparatively high, and the yields of the products are also very
good. On the other hand, 6-morpholino uracils are the least reac-
tive, and the yields of the products are not good. Moreover, the
reactivity of N,N-dimethylbarbituric acid 4a is much better than
that of N-methylbarbituric acid 4b.Table 1
Synthesis of novel spirosubstituted pyrido-[2,3-d]pyrimidines 5
Product [X]n R1 Time (h) Yield (%) (Appearance)a mp C
5a [CH2]1 Me 4 70 (orange) 267–269
5b [CH2]0 Me 3 75 (yellow) 274–275
5c [O]1 Me 4 60 (yellow) 281–283
5d [CH2]1 H 5 50 (orange) 312–315
5e [CH2]0 H 5 58 (yellow) 325–327
5f [O]1 H 5 40 (yellow) 342–345
5g — Me 3 70 (yellow) 237–239
5h — H 5 50 (yellow) 295–297
a All are crystalline compounds.
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Scheme 2.A plausible mechanism for the cyclisation step is outlined in
Scheme 2. The Knoevenagel condensation of 3a with 4a gives an
aminodiene system [A], which under thermolytic conditions
undergoes an internal redox process to generate a 1,6-dipole
through a 1,5-hydride shift (sigmatropic shift), and is subsequently
cyclised to give the product 5a. Contrary to our earlier report,15
where a 1,5-dipole formed via a 1,6-hydride shift, in the present
case a 1,6-dipole formed via a 1,5-hydride shift. This can be ex-
plained by the fact that the 1,6-sigmatropic shift is not possible
in the present case to generate the 1,5-dipole. Moreover, the carb-
anion formed in the present case is stabilised by the adjacent car-
bonyl groups. Thus, we obtained selectively the pyrido[2,3-
d]pyrimidine ring system during the cyclisation process.
Further study of the reaction is in progress. In conclusion, we
have reported the synthesis of some novel classes of spirosubsti-
tuted pyrido[2,3-d]pyrimidines by exploring the ‘tertiary amine ef-
fect’ reaction strategy under thermal conditions. A suitable
mechanism is given for the cyclisation process. This reaction,
which can be further explored for the synthetic manipulation of
many heterocyclic compounds of biological signiﬁcance, is a valu-
able addition to the chemistry of heterocyclic compounds in gen-
eral and uracils in particular.
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